Merck: good news from the FDA
(CercleFinance.com) - Merck has said that the US Food and Drug Administration has accepted for review a new supplemental license application for its Gardasil vaccine for the prevention of certain cancers and diseases caused by human papillomavirus (HPV).
The application is seeking approval for an expanded age indication for Garasil 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine HPV types covered by the vaccine, the US drugmaker said.
Merck also announced that FDA has approved its blockbuster
Keytruda for the treatment of patients with recurrent or metastatic cervical cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The application is seeking approval for an expanded age indication for Garasil 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine HPV types covered by the vaccine, the US drugmaker said.
Merck also announced that FDA has approved its blockbuster
Keytruda for the treatment of patients with recurrent or metastatic cervical cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.